Jeil Pharmaceutical’s new diabetes type I drug development selected as MOHW’s project
‘JP -2266,’ a new oral diabetes type I drug being developed by Jeil Pharmaceutical(CEO/President Seok-Jae Sung), was selected as the Ministry of Health and Welfare’s high-tech medical technology development(new drug development support) project.
As being selected as a new supported project, ‘JP-...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
